Bbc Chair Was Shareholder In Firm Awarded £600K While He Was A No 10 Adviser

[Gromit]

Oh, this doesn’t look good. The sleaze and corruption is never ending.

// Richard Sharp owns a multimillion pound stake in a healthcare company which was granted nearly £600,000 for Covid research while Sharp worked in Number 10, it has emerged.

Sharp, the chair of the BBC, is the second largest shareholder in Oncimmune, a cancer detection company which received funds in 2020 to help research Covid-19 vaccines and treatments. He was previously a director at the company. //

[bobbinwales]

I'll ask my company pension whether I'm a shareholder indirectly too

[jno]

there must be some way you can weaponise it to be made chairman of AB, bobb?

[Gromit]

Surely you might remember if you were a director at a company which subsequently got a £600,000 contract ?

[THECORBYLOON]

BOB, if your company pension scheme owns shares in a company, you have no personal control over those shares, do you?

[Deskdiary]

Earth shattering news, will parliament ever recover.

[Peter Pedant]

yeah you are meant to put them in a 'blind trust'
to avoid conflict

I cant get worked up about this sozza

[jno]

perhaps the question is whether the BBC will ever recover. The Tories have been trying to crush it for years and now they're trying to do it from within.

[Hymie]

[youngmafbog]

Give it a rest Hymie, you are looking ridiculous now.

[youngmafbog]

So this fella is a shareholder not a director as you are trying to imply.

I know your financial acumen is very low Gromit but I thought even you would understand that a shareholder doesnt have any say as an individual.

[Gromit]

// In May 2020, Sharp left his job as a non-executive director at Oncimmune to take up a role in Downing Street advising Sunak.
He kept his shareholding in Oncimmune, which was £3.8m at the time he left the company, and is now worth about £3.4m.

Just three months after Sharp left the company for government, Oncimmune announced it had won government funding to help adapt its technology to predict how people’s immune systems might respond to Covid-19 vaccines and treatments.